Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica — J Child Neurol
Posted on October 10, 2012
Filed under Spectrum
Filed under Spectrum
Naznin A.
Naznin A.
OBJECTIVE: Neuromyelitis optica (NMO) is an inflammatory disease associated with optic neuritis and myelitis. Although some studies have reported multiple sclerosis (MS)-like lesions in 10-30% of NMO patients, brain MRI is usually normal. Several studies have observed metabolic abnormalities on MR spectroscopy in MS, even in normal-appearing white matter (NAWM).
Neuromyelitis optica is a central nervous system disease characterized by optic neuritis and transverse myelitis. It is a devastating illness, and early treatment may prevent future relapses and severe disability. However, there is much variability in protocols used for treatment.
Background: NMO-IgG autoantibody is now considered a useful serum biomarker of neuromyelitis optica (NMO). A series of clinical and pathological observations suggest that NMO-IgG may play a central role in NMO physiopathology. Objective: The aim of this in vitro-based study was to characterize molecular and functional consequences of interaction between NMO-IgG and primary cultures of astrocytes.
OBJECTIVE: To evaluate serum and cerebrospinal fluid (CSF) NAA concentrations in patients with different demyelinating disease phenotypes and to correlate them with clinical measures. BACKGROUND: NAA is considered a marker of the functional integrity of neuronal mitochondrial metabolism that is mainly catabolised in oligodendrocytes. Normal appearing white matter (NAWM) damage, reported in MS but not in NMO by MRI studies, is associated with decreased brain NAA levels.
Background and purpose: Neuromyelitis optica (NMO) or Devic??s disease is a rare inflammatory and demyelinating autoimmune disorder of the central nervous system (CNS) characterized by recurrent attacks of optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM), which is distinct from multiple sclerosis (MS). The guidelines are designed to provide guidance for best clinical practice based on the current state of clinical and scientific knowledge